Orphenadrine hydrochloride structure
|
Common Name | Orphenadrine hydrochloride | ||
---|---|---|---|---|
CAS Number | 341-69-5 | Molecular Weight | 305.84200 | |
Density | 1.014g/cm3 | Boiling Point | 363ºC at 760mmHg | |
Molecular Formula | C18H24ClNO | Melting Point | 156 - 157ºC | |
MSDS | Chinese USA | Flash Point | 107.1ºC | |
Symbol |
GHS06 |
Signal Word | Danger |
Use of Orphenadrine hydrochlorideOrphenadrine hydrochloride is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with Ki of 6.0 ±0.7 μM.IC50 value: 6.0 ±0.7 μM (Ki)Target: NMDA ReceptorOrphenadrine has been used as an antiparkinsonian, antispastic and analgesic drug. Orphenadrine inhibits [3H]MK-801 binding to the phencyclidine (PCP) binding site of the N-methyl-D-aspartate (NMDA)-receptor in homogenates of postmortem human frontal cortex with a Ki-value of 6.0 ±0.7 μM. The NMDA receptor antagonistic effects of orphenadrine were assessed using concentration- and patch-clamp techniques on cultured superior colliculus neurones. Orphenadrine blocked open NMDA receptor channels with fast kinetics and in a strongly voltage-dependent manner. The IC50-value against steady state currents at -70 mV was 16.2 ± 1.6 μM (n = 6). [1]. Orphenadrine competitively inhibited [3H]nisoxetine binding in rat vas deferens membranes (Ki = 1.05 ±0.20 μM). It can be concluded that orphenadrine, at low micromolar concentrations, interacts with the noradrenaline reuptake system inhibiting its functionality and thus potentiating the effect of noradrenaline [2]. |
Name | orphenadrine hydrochloride |
---|---|
Synonym | More Synonyms |
Description | Orphenadrine hydrochloride is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with Ki of 6.0 ±0.7 μM.IC50 value: 6.0 ±0.7 μM (Ki)Target: NMDA ReceptorOrphenadrine has been used as an antiparkinsonian, antispastic and analgesic drug. Orphenadrine inhibits [3H]MK-801 binding to the phencyclidine (PCP) binding site of the N-methyl-D-aspartate (NMDA)-receptor in homogenates of postmortem human frontal cortex with a Ki-value of 6.0 ±0.7 μM. The NMDA receptor antagonistic effects of orphenadrine were assessed using concentration- and patch-clamp techniques on cultured superior colliculus neurones. Orphenadrine blocked open NMDA receptor channels with fast kinetics and in a strongly voltage-dependent manner. The IC50-value against steady state currents at -70 mV was 16.2 ± 1.6 μM (n = 6). [1]. Orphenadrine competitively inhibited [3H]nisoxetine binding in rat vas deferens membranes (Ki = 1.05 ±0.20 μM). It can be concluded that orphenadrine, at low micromolar concentrations, interacts with the noradrenaline reuptake system inhibiting its functionality and thus potentiating the effect of noradrenaline [2]. |
---|---|
Related Catalog | |
References |
Density | 1.014g/cm3 |
---|---|
Boiling Point | 363ºC at 760mmHg |
Melting Point | 156 - 157ºC |
Molecular Formula | C18H24ClNO |
Molecular Weight | 305.84200 |
Flash Point | 107.1ºC |
Exact Mass | 305.15500 |
PSA | 12.47000 |
LogP | 4.46460 |
Storage condition | 2-8°C |
Stability | Stable. Incompatible with strong oxidizing agents. |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H301 |
Precautionary Statements | Missing Phrase - N15.00950417 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
Hazard Codes | Xn |
Risk Phrases | R22 |
Safety Phrases | S36 |
RIDADR | 3249 |
RTECS | KR6300000 |
Packaging Group | III |
Hazard Class | 6.1(b) |
HS Code | 2922199090 |
HS Code | 2922199090 |
---|---|
Summary | 2922199090. other amino-alcohols, other than those containing more than one kind of oxygen function, their ethers and esters; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.
Exp. Neurol. 255 , 96-102, (2014) Although the sodium channel blocker mexiletine is considered the first-line drug in myotonia, some patients experiment adverse effects, while others do not gain any benefit. Other antimyotonic drugs a... |
|
Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: an open-label pilot study.
Audiol. Neurootol. 17(3) , 179-88, (2012) Tinnitus, the phantom perception of sounds, is a highly prevalent disorder. Although a wide variety of drugs have been investigated off label for the treatment of tinnitus, there is no approved pharma... |
|
Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656.
Naunyn Schmiedebergs Arch. Pharmacol. 376(4) , 275-84, (2007) The anticholinergic antiparkinson drug orphenadrine is an antagonist at central and peripheral muscarinic receptors. Orphenadrine intake has recently been linked to QT prolongation and Torsade-de-Poin... |
N,N-Dimethyl-2-(2-methylbenzhydryloxy)ethylamine Hydrochloride |
MFCD00012480 |
Mefenamin hydrochloride |
Orphenadrinehydrochloride |
Orphenadrine |
EINECS 206-435-4 |
Mebedrol |
orphenadrine*HCl |
N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine,hydrochloride |
Mephenamine hydrochloride |
Mephenamin hydrochloride |
Mephenamine |
Orphenadrine hydrochloride |
Disipal |
Orfenadrin hydrochloride |
Mephenamin |